Impax Laboratories Inc. (IPXL)

19.70
0.20 1.00
NASDAQ : Health Technology
Prev Close 19.90
Open 19.90
Day Low/High 19.65 / 20.30
52 Wk Low/High 12.70 / 25.70
Volume 451.10K
Avg Volume 904.20K
Exchange NASDAQ
Shares Outstanding 73.87M
Market Cap 1.49B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Impax Laboratories Reaches Analyst Target Price

Impax Laboratories Reaches Analyst Target Price

In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $20.00, changing hands for $20.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax...

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Impax Laboratories, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Impax...

Impax Announces Consent Solicitation

Impax Announces Consent Solicitation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Impax Laboratories, Inc. To Amneal Pharmaceuticals LLC Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of An Investigation Concerning Whether The Sale Of Impax Laboratories, Inc. To Amneal Pharmaceuticals LLC Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Impax Laboratories, Inc.

Short Interest Drops 16% For IPXL

Short Interest Drops 16% For IPXL

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 1,267,098 share decrease in total short interest for Impax Laboratories Inc , to 6,715,215, a decrease of 15.87% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Impax Shares Jump on Merger Buzz

Impax Shares Jump on Merger Buzz

Impax's shares soar after the Wall Street Journal reported that the drug maker is in merger discussions with Amneal Pharmaceuticals.

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Shanghai Fosun Pharmaceutical owns 3.85 million shares, according to a 13G filing.

TheStreet Quant Rating: D (Sell)